Abstract: A process for preparing a compound represented by general formulae (5) and (6) in the following reaction scheme or salts thereof, wherein R1 represents a protective group for a nitrogen atom; R2 represents a methanesulfonyl group or p-toluenesulfonyl group; R3 represents a hydrogen atom, an aralkyl group, or an alkyl group having 1 to 6 carbon atoms; and X represents a halogen atom. Reaction Scheme: The above process is useful as an industrial process for preparing intermediates of anticoagulant aromatic amidine derivatives described in Japanese Patent Application Laid-Open (kokai) No. 208946/1993.

Abstract: 2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Abstract: The present invention provides methods and compositions, i.e. synthetic libraries of candidate compounds, useful in the discovery and optimization of compounds which catalyze at least one chemical transformation. In certain instances, the subject compounds catalyze a chemoselective, regioselective, stereoselective or enantioselective transformation.

Abstract: There is disclosed a method for producing an essentially enantiomerically pure N-protected-azetidine-2-carboxylic acid of formula (1): which method is characterized by: subjecting a crude enantiomerically excess N-protected-azetidine-2-carboxylic acid comprising said enantiomer represented by formula (1) in excess to the other enantiomer thereof to crystallization in an organic solvent selected from aromatic hydrocarbon, aliphatic ether, aliphatic alcohol, aliphatic ketone, aliphatic nitrile, aliphatic amide, aliphatic sulfoxide, aliphatic ester and a mixed solvent thereof, wherein R is: an optionally substituted alkyl, alicyclic or alicyclicalkyl group, an optionally substituted alkenyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, or a dialkylamino group, and absolute configuration of the asterisked asymmetric carbon atom is S or R.

Abstract: Novel meta substituted arylalkylamine compounds are disclosed. These compounds can be administered as small molecule drugs to treat diseases or conditions associated with insufficient serotonin mediated nerve transmission (e.g., depression and obesity).

Abstract: 6-Amino-3-azabicyclo[3.1.0]hexanes of the formula wherein R1 and R2 independently of one another are C3-C4-alkenyl or Ar—CH(R′)— where R′ is hydrogen or C1-C4-alkyl and Ar is an optionally substituted C6-C10-aryl and R3 is hydrogen, C3-C4-alkenyl, Ar—CH(R′)— where R′ is hydrogen or C1-C4-alkyl and Ar is an optionally substituted C6-C10-aryl or COOR4 where R4 is C1-C4-alkyl or C2-C4-alkenyl. The invention also relates to a method for making these compounds and a method for using them.

Abstract: The present invention relates to a method for the synthesis of the dihydroindole C-ring found in CC-1065/duocarmycin analogs.

Abstract: Compounds of formula (I), and their pharmaceutically acceptable derivatives, wherein R1 and R2 are optional substituents and independently represent C1-6 alkyl, C2-6 alkenyl, optionally substituted by CO2H or CO2(C1-6 alkyl), C2-6 alkynyl, halogen, C1-3 perfluoroalkyl, (CH2)mAr1, (CH2)mHet1, (CH2)mCONR7R8, (CH2)mCO2R8, O(CH2)qCO2R8, (CH2)mCOR8, (CH2)mOR8, O(CH2)pOR8, (CH2)mNR7R8, CO2(CH2)qNR7R8, (CH2)mCN, S(O)nR8, SO2NR7R8, CONH(CH2)mAr1 or CONH(CH2)mHet1; R3 represents H, C1-6 alkyl, (CH2)pNR9R10, SO2R10, SO2NR9R10, (CH2)mCO2R10, C2-6 alkenyl, C2-6 alkynyl, (CH2)mCONR9R10, (CH2)mCO2R10, (CH2)pCN, (CH2)pR10 or (CH2)pOR10; R4 represents H or C1-6 alkyl; R5 represents H or OH; R6 represents phenyl optionally fused to a herterocyclic ring, the group as a whole being optionally substituted; R7-10 are fully defined herein and may independently represent Ar2 or Het2; Z represents CO2H, CONH(tetrazol-5-yl), CONHSO2O(C1-4 alkyl), CO2Ar3, CO2(C1-6 alkyl), tetrazol-5-yl, CONHSO2Ar3, CONHSO2(CH2)qAr3 o

Abstract: The present invention is concerned with a novel process for the preparation of the hydroxybenzothiophene of formula I comprising cyclocarbonylation of a compound of formula II wherein Y is as defined in the specification, followed by saponification. The compound of Formula I is a building block of pharmaceutically active substances, e.g. 5-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenylmethyl]-2,4-thiazolidinedione and the corresponding sodium salt which are from agents useful in the treatment of diabetes.

Abstract: A process for preparing 5-hydroxymethyl-2-oxazolidinone (1), preferably optically active, in one step from 3,4-boronic acid ester protected 3,4-dihydroxybutyramides (2) is described. The oxazolidinone is important in the pharmaceutical industry especially in the areas of antimicrobials and behavioral disorders.

Abstract: The present invention relates to the imidazole derivative of the following formula (I) wherein R1 is hydrogen, optionally substituted alkyl and the like, R2 is hydrogen, optionally substituted alkyl and the like, R3is optionally substituted heteroaryl, R4 is optionally substituted cycloalkyl, optionally substituted phenyl and the like, provided that when R1 is hydrogen, and R2 and R4 are the same or different and each is phenyl or phenyl substituted by halogen atom, lower alkyl or lower alkoxy, R3 is benzothiazolyl or thiazolyl substituted by phenyl, the imidazole derivative of the following formula (XII) wherein R6 is optionally substituted phenyl or optionally substituted heteroaryl and R7 is substituted phenyl, and pharmaceutically acceptable salts thereof.

Abstract: A process for preparing a compound represented by formula (I), wherein R1 represents straight-chain or branched C1-5 alkyl, C1-5 haloalkyl, or C3-6 cycloalkyl, and R2 represents C1-3 alkyl or C1-3 haloalkyl.

Abstract: Tetrazolinonecarboxamides of formula I wherein Het is oxetan-3-yl, thietan-3-yl, tetrahydrofuran-3-yl, furan-3-yl, tetrahydrothiophen-3-yl, thiophen-3-yl, tetrahydro-2H-pyran-3-yl, tetrahydro-2H-thiopyran-3-yl, tetrahydro-2H-pyran-4-yl or tetrahydro-2H-thiopyran-4-yl, in each case with or without substitution; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, phenyl, or 3- to 7-membered heterocyclyl; R2 is hydrogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, or is optionally substituted cycloalkyl, cycloalkylalkyl, phenyl, phenylalkyl, 3- to 7-membered heterocyclyl, or 3- to 7-membered heterocyclylalkyl, their preparation and herbicidal compositions comprising them.

Abstract: The present invention describes a method of organic synthesis for N-homocysteine thiolactonyl retinamide, a compound that has anticancer and antiatherogenic properties.

Abstract: An industrial process for preparing an oxazolidin-2-one derivative represented by the following general formula (3) wherein R1, R2, R3 and R4 are hydrogen atom, straight, branched or cyclic alkyl group, straight or branched alkyl group substituted by alkoxy, substituted amino or alkylthio, substituted or unsubstituted aralkyl group, or substituted or unsubstituted aryl group, and R5 is are hydrogen atom, straight, branched or cyclic alkyl group, substituted or unsubstituted aralkyl group, or substituted or unsubstituted aromatic ring, which is characterized in reacting a 1,3-dioxolan-2-one derivative and a carbamate derivative or an urea derivative in the presence of a fluoride salt.

Abstract: An organic compound having a nitroxide free radial of the formula (2) is prepared by reacting a cyclic secondary amine having a steric hindrance of the formula (1) with a peroxide in the presence of at least 1 part by weight of an organic compound having a cyano group per 1 part by weight of the cyclic secondary amine having the steric hindrance. In the formulae (1) and (2), T is a methylene group, an ethylene group, an oxygen atom or a methyleneoxy group; R is an alkyl group, an aralkyl group, an aryl group, a cycloalkyl group, an alkoxy group, an acyl group an acyloxy group, an amino group, a hydroxyl group or a heterocyclic group; R1, R2, R3 and R4 are the same or different and each an alkyl group or an aryl group, or R1 and R2 and/or R3 and R4 together form a tetramethylene group or a pentamethylene group; and n is an integer of 0 to 6.

Abstract: A process for preparing a 3-hydroxy-&ggr;-butyrolactone derivative represented by the following formula (1): wherein R is C1-C6 alkyl, 3 to 6-membered cycloalkyl, aralkyl, 2-alkenyl, acyl, &agr;-hydroxyalkyl, alkoxycarbonylalkyl or alkoxycarbonyl, which is characterized in treating 3-hydroxy-&ggr;-butyrolactone with a metal salt of hexamethyldisilazane and then, reacting it with an electrophilic reagent, optionally in the presence of a reaction promoter.

Abstract: Described is a process for preparing mixtures of mixed-alkylated methylolated 4,5-dihydroxyimidazolidin-2-ones by reaction of methylolated 4,5-dihydroxyimidazolidin-2-one (DMDHEU) with a monohydric C1-5 alcohol and a polyol selected from the group consisting of ethylene glycol, diethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, glycerol and polyethylene glycols of the formula HO(CH2CH2O)nH where 3≦n≦20, the monohydric C1-5 alcohol and the polyol each being used in an amount of from 0.1 to 2.0 mol equivalents, based on DMDHEU, and the reaction being carried out at temperatures from 20° C. to 70° C. and at a pH of from 1 to 2.5, and the pH being set to a value of from 4 to 8 after the reaction.

Abstract: The present invention relates to compounds of formula I provided that R1 and R2 not simultaneously stand for phenyl, the use thereof in, for example, electroluminescent devices and as void detection compounds.

Abstract: The present invention relates to a novel method for producing a compound of the formula [11] wherein R is an optionally substituted aromatic hydrocarbon group, an optionally substituted alicyclic hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted condensed heterocyclic group, which is useful as a therapeutic agent for diabetes. The method of the present invention is an industrially utilizable method that enables efficient production of the objective compound [11] from &bgr;-methyl L-aspartate via an important intermediate compound [6] wherein R is as defined above, at high yield.